Magenta Therapeutics (MGTA) receives clinical hold letter from FDA related to IND to initiate Phase 1/2 clinical trial of MGTA-117 in patients with AML and MDS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. DPZ
6. NVDA
7. PRIM
8. META
9. SPY
10. SPCX

Go back to Magenta Therapeutics (MGTA) receives clinical hold letter from FDA related to IND to initiate Phase 1/2 clinical trial of MGTA-117 in patients with AML and MDS

FDA's Clinical Hold Doesn't Affect Magenta Therapeutics' (MGTA) MGTA-117 Prospects - Analyst

July 21, 2021 10:51 AM EDT

On July 21st, 2021, Magenta Therapeutics, Inc. (Nasdaq: MGTA) announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase 1/2 clinical trial of MGTA-117 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

In the letter, the FDA is requiring that Magenta develop an additional bioassay to be used in... More

Magenta Therapeutics (MGTA) to Resume Trading at 8:30 a.m.

July 21, 2021 8:08 AM EDT

Magenta Therapeutics (NASDAQ: MGTA) to Resume Trading at 8:30 a.m.

... More